$SAVA
CASSAVA SCIENCES INC

2020 Q3 Form 10-Q Financial Statement

#000106953020000045 Filed on August 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q3 2020 Q2 2019 Q2
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.040M $820.0K $850.0K
YoY Change 25.3% -3.53% -15.0%
% of Gross Profit
Research & Development $308.0K
YoY Change -78.9%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.437M $1.163M $1.153M
YoY Change 84.47% 0.87% -53.13%
Operating Profit -$1.437M -$1.163M -$1.153M
YoY Change 84.47% 0.87%
Interest Expense $10.00K $30.00K $90.00K
YoY Change -87.5% -66.67% 800.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.430M -$1.140M -$1.060M
YoY Change 104.29% 7.55% -56.73%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$1.430M -$1.136M -$1.059M
YoY Change 105.16% 7.27% -56.81%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$57.27K -$46.00K -$61.77K
COMMON SHARES
Basic Shares Outstanding 24.92M 24.78M 17.22M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q3 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $24.10M $25.30M $18.50M
YoY Change 35.39% 36.76% 92.71%
Cash & Equivalents $24.07M $25.25M $18.53M
Short-Term Investments
Other Short-Term Assets $997.0K $186.0K $49.00K
YoY Change 158.96% 279.59% -51.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $25.07M $25.44M $18.58M
YoY Change 37.84% 36.9% 91.58%
LONG-TERM ASSETS
Property, Plant & Equipment $12.00K $13.00K $75.00K
YoY Change -80.33% -82.67% -25.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $12.00K
YoY Change
Total Long-Term Assets $328.0K $58.00K $222.0K
YoY Change 76.34% -73.87% 122.0%
TOTAL ASSETS
Total Short-Term Assets $25.07M $25.44M $18.58M
Total Long-Term Assets $328.0K $58.00K $222.0K
Total Assets $25.40M $25.50M $18.81M
YoY Change 38.23% 35.59% 91.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $465.0K $416.0K $594.0K
YoY Change 36.76% -29.97% -40.6%
Accrued Expenses $558.0K $755.0K $179.0K
YoY Change 34.46% 321.79% -40.33%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.168M $1.314M $937.0K
YoY Change 28.78% 40.23% -27.92%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $300.0K $0.00
YoY Change
Total Long-Term Liabilities $300.0K $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.168M $1.314M $937.0K
Total Long-Term Liabilities $300.0K $0.00 $0.00
Total Liabilities $1.426M $1.314M $982.0K
YoY Change 53.33% 33.81% -24.46%
SHAREHOLDERS EQUITY
Retained Earnings -$172.3M -$170.9M -$166.4M
YoY Change 3.13% 2.7%
Common Stock $26.00K $25.00K $17.00K
YoY Change 52.94% 47.06%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $23.97M $24.18M $17.82M
YoY Change
Total Liabilities & Shareholders Equity $25.40M $25.50M $18.81M
YoY Change 38.23% 35.59% 91.89%

Cashflow Statement

Concept 2020 Q3 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$1.430M -$1.136M -$1.059M
YoY Change 105.16% 7.27% -56.81%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change
Cash From Operating Activities -$2.200M -$800.0K -$600.0K
YoY Change 214.29% 33.33% -50.0%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $300.0K
YoY Change
Cash From Investing Activities $0.00 $300.0K $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.000M 200.0K 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -2.200M -800.0K -600.0K
Cash From Investing Activities 0.000 300.0K 0.000
Cash From Financing Activities 1.000M 200.0K 0.000
Net Change In Cash -1.200M -300.0K -600.0K
YoY Change 71.43% -50.0% -50.0%
FREE CASH FLOW
Cash From Operating Activities -$2.200M -$800.0K -$600.0K
Capital Expenditures $0.00 $0.00
Free Cash Flow -$800.0K -$600.0K
YoY Change 33.33%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei City Area Code
CityAreaCode
512
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
dei Document Type
DocumentType
10-Q
dei Entity Address Address Line1
EntityAddressAddressLine1
7801 N. Capital of Texas Highway
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 260
dei Entity Address City Or Town
EntityAddressCityOrTown
Austin
dei Entity Central Index Key
EntityCentralIndexKey
0001069530
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
24919333
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity File Number
EntityFileNumber
000-29959
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Registrant Name
EntityRegistrantName
CASSAVA SCIENCES INC
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
91-1911336
dei Local Phone Number
LocalPhoneNumber
501-2444
dei Security12b Title
Security12bTitle
Common Stock, $0.001 par value
CY2019Q2 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
308000
sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
1135000
CY2020Q2 sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
591000
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Trading Symbol
TradingSymbol
sava
CY2020Q2 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1100000
sava Research And Development Expense Net Of Grant Reimbursement
ResearchAndDevelopmentExpenseNetOfGrantReimbursement
882000
CY2019Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q1 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q2 sava Common Stock Net Income Loss Shares
CommonStockNetIncomeLossShares
CY2020Q1 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
2888092
CY2020Q2 sava Common Stock Warrant Shares Exercise
CommonStockWarrantSharesExercise
189431
sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
45000000
CY2019Q2 sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
22500000
sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
45000000
CY2020Q2 sava Operating Lease Liability Non Current Reduction And Offsetting Reduction Right Of Use Assets
OperatingLeaseLiabilityNonCurrentReductionAndOffsettingReductionRightOfUseAssets
22500000
CY2020Q2 sava Operating Leases Future Minimum Payments Imputed Interest
OperatingLeasesFutureMinimumPaymentsImputedInterest
5000
CY2020Q2 sava Operating Leases Future Minimum Payments Remainder Of Fiscal Year And Due In Two Years Total
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYearAndDueInTwoYearsTotal
50000
sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
2200000
CY2019Q2 sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
1400000
sava Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
2400000
CY2019Q1 sava Shares Issued Costs From Sale2018 Sale Of Common Stock And Warrants
SharesIssuedCostsFromSale2018SaleOfCommonStockAndWarrants
CY2019Q1 sava Stockholders Equity Issuance Of Common Stock And Warrants Net Of Issuance Costs
StockholdersEquityIssuanceOfCommonStockAndWarrantsNetOfIssuanceCosts
60000
CY2020Q1 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
3613000
CY2020Q2 sava Stockholders Equity Warrant Shares Exercise
StockholdersEquityWarrantSharesExercise
236000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
453000
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
416000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
777000
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
755000
CY2020Q2 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
878000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
190664000
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
195032000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
673000
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
329000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
522000
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
252000
CY2019Q4 us-gaap Assets
Assets
23486000
CY2020Q2 us-gaap Assets
Assets
25498000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
23349000
CY2020Q2 us-gaap Assets Current
AssetsCurrent
25440000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19807000
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18534000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23081000
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
25254000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1273000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
2173000
CY2019Q4 us-gaap Certificates Of Deposit At Carrying Value
CertificatesOfDepositAtCarryingValue
13000000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21841810
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24919333
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17219300
CY2019Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17219300
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21841810
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24729902
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24919333
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
25000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
30000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
20000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.06
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.09
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.05
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
58000
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
84000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
346000
CY2020Q2 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
246000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1722000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
845000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1596000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
818000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
300000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-37000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
23000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-22000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
26000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-184000
us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-82000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
14000
us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5000
us-gaap Interest And Other Income
InterestAndOtherIncome
186000
CY2019Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
94000
us-gaap Interest And Other Income
InterestAndOtherIncome
99000
CY2020Q2 us-gaap Interest And Other Income
InterestAndOtherIncome
27000
CY2020Q2 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.0550
CY2019Q4 us-gaap Liabilities
Liabilities
1387000
CY2020Q2 us-gaap Liabilities
Liabilities
1314000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23486000
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25498000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1387000
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
1314000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-60000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3849000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-18000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
360000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1195000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2036000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1359000
us-gaap Net Income Loss
NetIncomeLoss
-2418000
CY2019Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
17823000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-1059000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-1150000
us-gaap Net Income Loss
NetIncomeLoss
-2286000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-1136000
us-gaap Operating Expenses
OperatingExpenses
2604000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
1153000
us-gaap Operating Expenses
OperatingExpenses
2385000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
1163000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2604000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1153000
us-gaap Operating Income Loss
OperatingIncomeLoss
-2385000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-1163000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
90000
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
45000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
90000
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
45000
CY2020Q2 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
50000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
268000
CY2020Q2 us-gaap Other Assets Current
OtherAssetsCurrent
186000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
9000
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
14000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
60000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
18000
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
CY2019Q2 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
0
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
360000
CY2020Q2 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
260000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3849000
CY2020Q2 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
892000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
47000
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-168587000
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170873000
us-gaap Share Based Compensation
ShareBasedCompensation
673000
us-gaap Share Based Compensation
ShareBasedCompensation
522000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
22099000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24184000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
19628000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
22099000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24832000
CY2020Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24184000
us-gaap Use Of Estimates
UseOfEstimates
<div> <div style="margin-left:0pt;margin-right:0pt;"> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-weight:bold;font-style:italic;">Use of Estimates</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;font-family:Tahoma;font-style:italic;">&#xFEFF;</font><font style="display: inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:18pt;text-align:justify;text-justify:inter-ideograph;border-top:1pt none #D9D9D9 ;font-family:Times New Roman;font-size: 10pt"> <font style="display: inline;">The Company makes estimates and assumptions in preparing its financial statements in conformity with GAAP. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenue earned and expenses incurred during the reporting period. The Company evaluates&nbsp;its estimates on an ongoing basis, including those estimates related to agreements, research collaborations and investments. Actual results could differ from these estimates</font><font style="display: inline;color:#000000;"> and assumptions.</font><font style="display: inline;">&nbsp;</font> </p> <p><font size="1"> </font></p> </div> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17162000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17162000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24630000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24779000

Files In Submission

Name View Source Status
0001069530-20-000045-index-headers.html Edgar Link pending
0001069530-20-000045-index.html Edgar Link pending
0001069530-20-000045.txt Edgar Link pending
0001069530-20-000045-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
sava-20200630.xml Edgar Link completed
sava-20200630.xsd Edgar Link pending
sava-20200630x10q.htm Edgar Link pending
sava-20200630xex31_1.htm Edgar Link pending
sava-20200630xex31_2.htm Edgar Link pending
sava-20200630xex32_1.htm Edgar Link pending
sava-20200630_cal.xml Edgar Link unprocessable
sava-20200630_def.xml Edgar Link unprocessable
sava-20200630_lab.xml Edgar Link unprocessable
sava-20200630_pre.xml Edgar Link unprocessable
Show.js Edgar Link pending